Contineum Therapeutics (CTNM) Non-Current Assets (2023 - 2025)
Historic Non-Current Assets for Contineum Therapeutics (CTNM) over the last 3 years, with Q3 2025 value amounting to $5.9 million.
- Contineum Therapeutics' Non-Current Assets rose 56442.2% to $5.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.6 million, marking a year-over-year increase of 19031.8%. This contributed to the annual value of $6.5 million for FY2024, which is 14100.75% up from last year.
- Per Contineum Therapeutics' latest filing, its Non-Current Assets stood at $5.9 million for Q3 2025, which was up 56442.2% from $6.0 million recorded in Q2 2025.
- In the past 5 years, Contineum Therapeutics' Non-Current Assets registered a high of $6.5 million during Q4 2024, and its lowest value of $891000.0 during Q3 2024.
- Its 3-year average for Non-Current Assets is $4.1 million, with a median of $4.9 million in 2024.
- The largest annual percentage gain for Contineum Therapeutics' Non-Current Assets in the last 5 years was 56442.2% (2025), contrasted with its biggest fall of 5909.68% (2025).
- Quarter analysis of 3 years shows Contineum Therapeutics' Non-Current Assets stood at $2.7 million in 2023, then skyrocketed by 141.01% to $6.5 million in 2024, then decreased by 8.34% to $5.9 million in 2025.
- Its Non-Current Assets stands at $5.9 million for Q3 2025, versus $6.0 million for Q2 2025 and $6.1 million for Q1 2025.